简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe

2025-11-26 02:30

Sanofi SA's (NASDAQ:SNY) Paris headquarters received an unannounced visit on Tuesday as tax investigators, accompanied by prosecutors and specialist aides, searched the site amid a widening financial probe.

French prosecutors confirmed that Sanofi is the focus of a preliminary investigation launched in January 2024 into alleged "money laundering of tax fraud," including potential involvement by an organized group and possible criminal conspiracy, Le Monde reported.

The company said it used a Société Générale financing structure tied to an acquisition more than a decade ago — a structure now under scrutiny. Sanofi maintains that it has complied with all applicable laws, is preserving its legal rights, and will cooperate with authorities.

Also Read: Regeneron’s Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

On Tuesday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the European Commission (EC) approved Dupixent (dupilumab) for moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH) and who are naïve to anti-immunoglobulin E (IgE) therapy for CSU.

The approval is based on data from two Phase 3 clinical trials in the LIBERTY-CUPID program.

Both trials assessed Dupixent as an add-on therapy to standard-of-care antihistamines compared with antihistamines alone and demonstrated that Dupixent significantly reduced urticaria activity (a composite of itch and hives) and individual measures of itch and hive severity compared with placebo at 24 weeks.

Dupixent also increased the percentage of patients with well-controlled disease and complete response at 24 weeks compared to placebo.

Price Action: REGN stock is up 2.66% at $781.69, and SNY stock is up 1.55% at $49.91 at the last check on Tuesday.

Read Next:

  • Snowflake Acquires Data Startup Select Star To Boost Its AI And Cloud Capabilities

Photo: tolobalaguer.com on Shutterstock.com

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。